WEST LAFAYETTE, Ind., Dec. 18, 2018 (GLOBE NEWSWIRE) — Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the fourth quarter and twelve months ended September 30, 2018, prior to the market opening on Thursday, December 20, 2018.

If there are any questions after the press release is issued, please direct your comments to the investor relations contact noted in this release.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit www.BASinc.com for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company’s filings with the U.S. Securities and Exchange Commission.

Company Contact:
Jill C. Blumhoff
Chief Financial Officer
Phone: 756.497.8381
[email protected]